Table 2 Baseline characteristics
Characteristic | Allocation A (n = 5)* | Allocation B (n = 6)* | Overall (n = 11)* |
|---|---|---|---|
Age | 67.4 (60.7–89.6) | 64.3 (42.5–70.7) | 66.2 (42.5–89.6) |
Male | 4 (80.0%) | 2 (33.3%) | 6 (54.5%) |
Mutation | Â | Â | Â |
  ACVRL1 | 2 (40.0%) | 5 (83.3%) | 7 (63.6%) |
  Endoglin | 3 (60.0%)a | 1 (16.7%) | 4 (36.4%) |
Brain VM | 1 (20.0%) | 0 (0.0%) | 1 (9.1%) |
Pulmonary AVM | 1 (9.1%) | 1 (16.7%) | 3 (27.3%) |
Symptomatic liver VM | 1 (20.0%) | 2 (33.3%) | 3 (27.3%) |
GI bleeding | 4 (80.0%) | 2 (33.3%) | 6 (54.5%) |
Anemia (at enrollment and/or randomization) | 4 (80.0%) | 4 (66.7%) | 8 (72.7%) |
Enrollment ESS | 4.17 (2.43–5.43) | 5.69 (4.42–7.28) | 4.96 (2.43–7.28) |
Randomization ESS | 4.35 (3.44–4.53) | 4.60 (2.62–7.28) | 4.35 (2.62–7.28) |
IV iron infusions (during run-in) | 0 (0.0%) | 3 (50.0%) | 3 (27.3%) |
Mean infusion amount (mg) (during run-in) | NA | 300 (125–300) | 300 (125–300) |
Blood transfusions (during run-in) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Enrollment Hgb | 129 (111–148) | 121 (101–128) | 123 (101–148) |
Randomization Hgb | 133 (113–159) | 117 (100–132) | 126 (100–159) |
Mean weekly epistaxis duration | 28.7 (21.3–274.4) | 47.7 (17.8–142.1) | 34.3 (17.8–274.4) |